Abstract: (11302 Views)
Abstract
Background: Iron overload is a clinical consequence of repeated blood transfusions and causes significant organ
damage, morbidity, and mortality in the absence of proper treatment. The primary targets of Iron chelators used for
treating transfusional Iron overload are the prevention of Iron ingress into tissues and its intracellular scavenging.
The present study was aimed at elucidating the capacity of clinically important Iron chelator, deferoxamine to gain
access to intracellular Iron pools of key Iron accumulating cells (hepatocytes).
Material and methods: The study was conducted as an in vivo investigation. Iron-rich chow fed rats and regular
chow fed rats were given deferoxamine and hepatic Iron concentration was measured using atomic absorption
spectroscopy.
Results: In Iron-loaded rats, the results showed that deferoxamine did not alter hepatocyte Iron levels compared
with the control group but increased urinary excretion.
Conclusion: We conclude that short term deferoxamine treatment is ineffective in Iron removal from rat hepatocytes.
Key words: Deferoxamine, Iron overload, hepatocytes.
:
Original Article |
Subject:
Pediatric Hematology & Oncology Received: 2012/07/7 | Accepted: 2012/10/14 | Published: 2013/07/30